Related conditions

Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. Zand L et al. Leuk Lymphoma. 2015 Apr 10:1-27. [Epub ahead of print]. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Afrough A et al. Biol Blood Marrow Transplant. 2015 Apr 2. pii: S1083-8791(15)00225-6.…

Emerging treatments

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Laubach JP et al. Clin Cancer Res. 2015 Apr 15. pii: clincanres.3190.2015. [Epub ahead of print]. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Chon HJ et al. Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat…

Biology and genetics

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Walker BA et al. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Fujiwara S et al. Exp Hematol Oncol. 2015 Apr 21;4:12. doi: 10.1186/s40164-015-0008-z. eCollection 2015. Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA…

Supportive care

Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. Ford PA et al. J Clin Oncol. 2015 Apr 13. pii: JCO.2014.57.9912. [Epub ahead of print]. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosedmultiple myeloma patients with severe renal impairment. Zannetti BA et al. Am J Hematol. 2015 Apr 8. doi: 10.1002/ajh.24035.…

General

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Stetler-Stevenson M et al. Cytometry B Clin Cytom. 2015 Apr 23. doi: 10.1002/cyto.b.21249. [Epub ahead of print]. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Cejalvo MJ et al. Future Oncol. 2015 Apr 10:1-16. [Epub ahead of print]. Lenalidomide in multiple myeloma. Kim Y et al. Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407.…

Complications of myeloma and its treatments

Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Gracheva MA et al. Leuk Lymphoma. 2015 Apr 24:1-35. [Epub ahead of print]. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Keller S et al. Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00086-7. doi: 10.1016/j.leukres.2015.03.015. [Epub ahead of print]. Subcutaneous bortezomib in multiple myeloma patients induces similar…

Current treatments

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print]. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13.…